Article

Erin Crown, PA-C: The Difficulty in Treating Schizophrenia

Author(s):

A physician's assistant for Oasis Lifecare discusses some of the new and promissing treatments for schizophrenia.

Schizophrenia remains one of the more difficult psychiatric disorders to treat, largely because of the different symptoms attached to the disease, as well as the negative side effects like weight gain that come with the medications commonly used.

The disease is challenging largely because the symptoms can manifest so differently in individual patients. Some patients become delusional and hallucinate events that are removed from reality, other patients tend to crave social isolation and lack the ability for emotional responses.

Other comorbidities included paranoia, depression, and impaired motor functions.

While antipsychotics can be effective in treating patients with schizophrenia, the treatment themselves come with a number of side effects that cause schizophrenia patients to go off and on medications, depending on how some of the side effects are impacting their everyday lives.

These side effects include nausea, weight gain, dizziness, and blurred vision because antipsychotic medications change the way brain chemicals act in order to treat certain symptoms such as hallucinations or hearing voices.

In an interview with HCPLive®, Erin C. Crown, PA-C, a physician’s assistant for Oasis Lifecare, explained just why schizophrenia is so difficult to treat and what new treatments could be on the horizon to help this patient population.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.